syspharm retweeted
Modelling study shows high efficacy of #PrEP in women countries with high #HIV prevalence. Risk of infection could be reduced by more than 90%. Publication of an international research team led by the #RKI in @NatureMedicine.
nature.com/articles/s41591-0…
syspharm retweeted
Modeling shows that antiretroviral treatment as pre-exposure prophylaxis (PrEP) can be highly effective in cisgender women at preventing #HIV-1 acquisition, but underscores the need to understand the barriers that limit PrEP adherence in women. nature.com/articles/s41591-0…
syspharm retweeted
New work by Redmond Smyth lab @Helmholtz_HIRI: Comprehensive functional and structural probing of the HIV-1 5’ untranslated region reveals novel interactions that regulate RNA dimerization, Pr55Gag binding and genome packaging into virions. #openaccess nature.com/articles/s41594-0…
syspharm retweeted
Our Forschungsgruppe RobustCircuit is finally official! Thanks to @dfg_public and our speaker @HiesingerLab and all members from #Berlin @Wernet_Lab @SystemPharm, Sigrist lab, Petzoldt lab, Baum lab, Schreiber lab and #Mainz @marion_silies @crlttmrtll, Ryglewski lab Duch lab.
#DFG-#Forschungsförderung für acht neue #Forschungsgruppen: Die Verbünde erhalten insgesamt rd. 43,3 Mio. € für die erste #Förderperiode. Sie forschen u.a. zur Entwicklung des Gehirns, zu #Psychotherapie|erfolg sowie zu den Ursachen von #Hochwasser. Mehr: dfg.de/service/presse/presse…
syspharm retweeted
Congratulations to the @rki_de team led by MATH+ PI Max von Kleist on the publication in @NatureComms! They used a method, GInPipe, to estimate #SARS_CoV_2 incidences and the number of unreported cases. It is based on publicly available viral genomes.
➡️ go.nature.com/3ELy1wj
